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Breast cancer is the second leading cause of cancer death for women in developed 
countries, while autoimmune disease effects approximately 10 million people in the 
United States, of which approximately 80% are female.  Both diseases are associated 
with hormonal risk factors and are related to the divergent effects of the cellular and 
humoral immunity that is associated with the T-helper 1 and T-helper 2 immune 
response.  To investigate the potential implications that autoimmune disease may have 
on breast cancer-specific mortality, we have conducted a population-based 
retrospective cohort study of women who were diagnosed with breast cancer between 
January 1, 1996 to December 31, 2010 in South Carolina. 
Methods 
This study included 3,286 female breast cancer patients.  The participants were 
identified through administrative claims databases, the South Carolina Medicaid 
Program and the South Carolina State Employee Health Plan, and were linked by a 
unique identifier to the South Carolina Central Cancer Registry.  The autoimmune 
disease (AD) cohort was identified as those that had at least one AD present (n = 629), 
while those without an AD diagnosis were placed into a second cohort (n = 2,657).  A 
secondary analysis was performed identifying those with a T-helper 1 (Th1) dominant 
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AD and a T-helper 2 (Th2) dominant AD; these two groups were then compared to those 
without an AD present.  Kaplan Meier and Cox regression was used to test for 
associations between AD and breast cancer-specific survival.  
Results 
Breast cancer-specific survival was not significantly different between the AD and no AD 
cohorts.  However, the crude analysis showed a significant reduction in breast cancer 
mortality (54%) for those with a Th1 dominant AD compared to those without an AD.  
When controlling for chemotherapy and radiation therapy, the relationship remained 
significant with a 55% reduction in breast cancer mortality among those with a Th1 
dominant AD compared to those without an AD (HR: 0.45, 95% CI: 0.23, 0.87). 
Conclusion 
Among women who are diagnosed with breast cancer, the presence of a Th1 dominant 
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Introduction and Thesis Overview 
1.1 Introduction 
Breast cancer is the most common cancer among women in developed countries 
1.  In 2017, an estimated 252,710 women in the United States will be diagnosed with 
invasive breast carcinoma, accounting for 30% of all female cancer cases 2.  While 
survival rates for breast cancer have improved significantly over time, breast remains 
the second leading cause of cancer mortality among American women.  The American 
Cancer Society estimates that 282,500 women will die of cancer in 2017 with 40,610 of 
these deaths being attributed to breast cancer 2.  There are several known risk factors 
for breast cancer, however these only account for approximately 45% to 55% of the 
cases that occur 3. 
Epidemiological studies have indicated that the overall risk for developing breast 
carcinoma may be partially attributed to the immune status of the individual 4.  The 
immune system consists of both the innate and adaptive immune response, which work 
together to protect the body against disease5. An autoimmune disease (AD) occurs 
when the adaptive immune system fails to recognize the difference between what is 
foreign and what is self, resulting in an attack of healthy tissues5.   There are between 70 
to 100 identified autoimmune diseases.  It is estimated that approximately 10 million 
people in the United States, of which 80% are female, are effected by at least one AD 6.  
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There have been several hypotheses to why women are more likely to be affected by AD 
than men.  One proposed theory is the difference and fluctuations of sex hormones, as 
several studies have presented an association between remission and flares that occur 
with AD and the hormonal fluctuations that occur in women, such as during pregnancy 
and the menstrual cycle 7.   
Numerous studies have presented the associations between autoimmune 
disease and breast cancer risk, with conflicting results; however, little data exists 
regarding the association of AD with breast cancer survival.  This is an important gap in 
the literature, given the potential hormonal implications that both these diseases share 
in common. 
1.2 Significance of Research 
The primary objective of this study was to investigate the association of AD with 
breast cancer specific survival among a cohort of female breast cancer patients in South 
Carolina.  This research will provide insight into the relationship between AD prevalence 
and breast cancer survival.  There have been many studies conducted looking at 
individual ADs in their relationship to breast cancer risk, however, few have looked at 
survival, and to date no population-based studies have analyzed the potential 
association that the T-helper 1 (Th1) and T-helper 2 (Th2) dominant ADs have on breast 
cancer survival.  With over 70 identified ADs, the American Autoimmune Disease 
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Association states that only 24 ADs contain reputable epidemiological studies8.  In 
conducting an analysis on all potential ADs and those with Th1 and Th2 dominance, this 
will help to fill a major gap that currently exists in the literature.  
1.3 Thesis Overview 
This thesis is comprised of five chapters.  The first chapter provides a brief 
overview of the issues around AD and breast cancer, the primary purpose and objectives 
of this research, and a thesis overview.  The second chapter includes a background of 
the current literature for both AD and breast cancer, discussing the studies that have 
been conducted to analyze the association between AD and cancer, with a specific focus 
on those studies that relate to breast cancer.  This background information will provide 
information on the most relevant literature to help the reader in being able to critically 
evaluate the results and implications of this study.  The third chapter provides 
information regarding the study design, methodological details, and the statistical 
methods that were used.  The fourth chapter provides the results of the survival and 
multivariable analyses.  The final chapter will include the discussion, highlighting the 
limitations of the study and providing an overall conclusion with suggestions regarding 




Review of the Literature 
2.1 Autoimmune Disease and the Immune System 
The immune system is regulated by antigen presenting cells which are comprised 
of the innate and adaptive immunity9.  The innate immune response, consists of 
phagocytes, which include your macrophages, granulocytes, dendritic cells, and natural 
killer cells4.  The innate immune response communicates and activates the adaptive 
immune response in order to eliminate pathogens5.  There are two types of adaptive 
immune responses, the humoral immunity, comprised the B lymphocytes, and the 
cellular immunity, made up of T lymphocytes.  The B lymphocytes are programmed to 
create specific antibodies to target pathogens, while the T cells contribute to the 
immune defense by directing and regulating the immune response through the helper T 
cells, T-helper 1 (Th1) and T-helper 2 (Th2) cells10.  Autoimmune diseases occur when 
the B cells develop antibodies to the organs and/or tissues and therefore misidentify 
normal body tissues as invaders10. 
The Th1 cytokines secrete IFN-ꭚ, IL-2, and TNF-α to promote cellular immunity, 
while the Th2 cytokines secrete IL-4 and IL-10 to promote humoral immunity4,9.  Studies 
have shown that females tend to have stronger cellular and humoral immune response 
than that of men, therefore increasing their resistance to several infections but also 
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causing females to be more susceptible to developing an AD8,11.  Collectively AD effects 
three times more women than men8.  Approximately 80% of patients are women for 
Sjögren’s syndrome, Systemic lupus erythematosus, Primary biliary cirrhosis, 
Autoimmune thyroid disease, and Scleroderma, while 60% to 75% of patients are 
women for multiple sclerosis, myasthenia gravis, and rheumatoid arthritis 6.   
 
Table 2.1:  Gender prevalence ratio for various autoimmune diseases. 
Autoimmune Disease Ratio (female/male) Reference  
Addison’s Disease 12.3:1 11 
Antiphospholipid syndrome 9:1 7,11,12 
Autoimmune hepatitis 7.5 – 8:1 7,11–13 
Celiac disease 1.8 – 3.3:1 11,14 
Crohn’s disease 0.45 – 3:1 11 
Dermatomyositis 2:1 11,13 
Grave’s disease 2.7 – 4:1 11–13,15 
Hashimoto’s thyroiditis/hypothyroidism 5.2 – 50:1 7,11–13,15,16 
Mixed connective tissue disease 8:1 11,12 
Multiple Sclerosis 2 – 3:1 7,11,12 
Myasthenia gravis 1.6 – 3:1 6,7,11,12 
Primary biliary cirrhosis 9:1 8 
Rheumatoid arthritis 2.7 – 4:1 7,11–13,15,16 
Scleroderma 3 – 11.8:1  7,11–13,15 
Sjögren’s syndrome 9 – 20:1 7,11–13,15 
Systemic lupus erythematosus 7.4 – 9:1 6,7,11–13,15,16 
Thrombocytopenic purpura 2:1 8 




2.2 Breast Cancer and the Immune System 
Breast cancer is the result of malignant tumors developing in the breast 17.  
Breast cancer is the most common cancer among women, with a lifetime risk of 12% 
and a 5% risk of mortality18.  Studies have shown that fluctuations in the immune 
system may be associated with an increased risk of breast cancer.  Women with 
estrogen receptor positive breast cancer typically have a better prognosis than those 
with estrogen receptor negative breast cancer, with a 10% difference in 5-year 
survival19.  A study conducted on over 12,000 breast cancer patients in the United 
Kingdom and Canada found that among the women that had estrogen receptor negative 
tumors, the presence of CD8+ T cells within the tumor was associated with a significant 
reduction in breast cancer specific mortality reporting a hazard of 28% (95% CI: 16% - 
38%)20.  Additionally, studies have found that when T lymphocytes were present in 
malignant tumors the tumors were more likely to have negative auxiliary lymph nodes, 
have a smaller tumor diameter, a lower histological grade, and reoccurrence-free 
survival4.   
As mentioned previously, the T lymphocytes consists of the Th1 and Th2 
cytokines.  The Th1 cytokines enhance the antitumor immune response through the 
secretion of IFN-ꭚ, which causes the anti-tumor directed B cell factors and the CD8+ T 
cells to all work together to “favor tumor rejection”4.  In contrast, the chronic activation 
of the Th2 cytokines secrete pro-growth factors which will decrease the CD8+ T 
lymphocytes, resulting in tumor promotion4.  A study conducted by Campbell and 
colleagues analyzed the peripheral blood lymphocytes of 84 breast cancer patients and 
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26 healthy controls, finding that the Th1 cytokines were lower in the breast patients 
prior to therapy compared to healthy controls21.  The CD8+ T cytokines, Th1 cytokines, 
and natural killer (NK) cells are the key players in protecting the body against tumor 
development and progression, while the B and Th2 cytokines that are involved in the 
humoral immune response promote both tumor development and progression4.  
2.3 Breast Cancer and Autoimmune Disease 
The association that has been seen between the absence or decrease of T-helper 
cells and the increase risk of developing breast carcinoma suggests a possible 
beneficiary role that autoimmune diseases may implicate in potentially improving 
cancer prognosis, as studies have shown that there is an increase in T-helper cytokines 
for those with an AD.  It is widely accepted now in the scientific community, that both 
the Th1 and Th2 cytokines play a major role in coordinating the immune system.  The 
Th1/Th2 hypothesis began in the 1980s, when these two subgroups of T lymphocytes 
were recognized in mouse models22.  This concept was later investigated and connected 
to the role that both these cytokine subgroups play in the development of disease.  The 
Th1 pathways is considered the more aggressive of the two, and have been shown be 
the main coordinator in the attack against viruses, bacterial agents, and even cancer 
cells22.  This subgroup of T cells has been referred to as the “antitumor immune 
response”, which occurs when Th1 cytokines secrete IFN-ꭚ, resulting in an activation of 
macrophage cytotoxic activity4.  However, when the Th1 cells become overactive the 
resulting consequence can be the development of an organ-specific AD22.  The Th2 
pathway promotes humoral immunity and consists of major anti-inflammatory 
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Table 2.2:  T-helper 1 (Th1) dominant 
autoimmune diseases. 
Autoimmune Disease Reference 











Rheumatoid arthritis (RA) 
9,24,57,58,61 





cytokines, IL-4 and IL-109.  This pathway is thought to be involved in downregulating the 
cell-mediated anti-tumor response and enhancing the “protumor humoral response”4.  
The overactivation of the Th2 cytokines has been associated with increasing the risk of 
developing allergies, IgE-related diseases, as well as systemic ADs22. 
2.3.1 Th1 Dominant Autoimmune Diseases and Breast Cancer 
Autoimmune diseases, such as Multiple sclerosis, Rheumatoid arthritis, and Type 
I diabetes mellitus, have been associated with a Th1 dominant immune response.  
Several studies have looked at the association between these Th1 dominant ADs and 
pregnancy, as pregnancy tends to enhance the Th2 cytokines and reduce the Th1 
cytokines23.  This shift from a Th1 to a Th2 immune response, often causes those with 
Th1 associated AD to undergo remission during pregnancy.  However, during the 
postpartum period the Th1 related ADs will typically increase in severity23.  The ADs, RA, 
MS, Type I diabetes mellitus, and Crohn’s disease, have an excess of IL-12 and TNF-α, 
both of which are associated with the Th1 immune response.  Women with these ADs, 
experienced remission during the third trimester of pregnancy due to the increased 
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levels of cortisol which suppresses the pro-inflammatory cytokines, IL-12 and TNF-α, 
while promoting the anti-inflammatory cytokines, IL-4 and IL-1024.  
As mention previously, the Th1 immune response has been seen to be 
associated with the downregulation of tumor growth24.  Hemminki and colleagues 
conducted a study in Sweden, analyzing the risk and survival of female cancers among 
those women with an AD25.  Of the 199,466 patients that were studied, 4,607 patients 
developed breast cancer.  The standardized incidence ratio (SIR) was calculated as the 
ratio of what was observed in the Swedish Hospital Discharge Register to the ratio 
expected of that in the general population.  The overall risk for breast cancer was 
significantly lower for those with an AD, with an SIR of 0.94 (95% CI: 0.91 to 0.97).  Four 
of the six Th1 dominant ADs represented in this study had a significantly lower risk of 
developing breast cancer.  There was a 15% reduced risk seen in Crohn’s disease 
patients with an SIR of 0.85 (95% CI: 0.75 to 0.97).  Hashimoto’s thyroiditis patients had 
a significantly lower risk as well with an SIR of 0.78 (95% CI: 0.66 to 0.91)25.  In addition, 
a cohort study conducted in Ontario, Canada identified 178,186 women with breast 
cancer and found that those with hypothyroidism had a significantly lower risk of dying 
compared to those that did not have hypothyroidism (HR: 0.87, 95% CI: 0.77 to 0.98)1.  
Hemminki and colleagues similarly found a significantly reduced risk for developing 
breast cancer among women with RA (SIR: 0.84, 95% CI: 0.79 to 0.89), results which 
were consistent with a study conducted through the Danish Cancer Registry25,26.  
However, Ji and colleagues found that those with RA compared to those without RA had 




Table 2.3:  T-helper 2 (Th2) dominant 
autoimmune diseases. 










Systemic lupus erythematosus 
(SLE) 
22,24,57,63,64 




specific survival and 1.55 (95% CI: 1.40 to 1.71) for overall survival27.  In addition to 
Crohn’s disease, Hashimoto’s thyroiditis, and RA, those patients with Sögren’s syndrome 
had a significantly reduced risk as well, with an SIR of 0.46 (95% CI: 0.26 to 0.75)25. 
2.3.2 Th2 Dominant Autoimmune Diseases and Breast Cancer 
While, the Th1 dominant ADs that were represented in Hemminki and colleagues 
study were either not significant or provided results that showed a significant reduction 
in risk of developing breast cancer, two of the six Th2 dominant ADs represented in this 
study had a significantly higher risk of developing AD while the other Th2 ADs that were 
represented did not yield significant results.  Grave’s disease had a significant SIR of 1.13 
(95% CI: 1.06 to 1.21), while ulcerative colitis had a significant SIR of 1.12 (95% CI: 1.01-
1.24)25.  While ulcerative colitis had a significant increase in risk for developing breast 
cancer, those patients with ulcerative colitis had a 25% reduced risk of dying compared 
to the general population (HR: 0.75, 95% CI: 0.58 to 0.98)25.  While systemic lupus 
erythematosus (SLE), did not yield significant results in the previously mentioned study, 
a study conducted on the Chicago Lupus Cohort found that even after controlling for 
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hormone replacement therapy and oral contraceptive history, women with lupus had a 
higher risk of developing breast cancer26.  
2.3.3 Breast Cancer and Autoimmune Disease Risk Factors 
Autoimmune diseases are estimated to effect approximately 3% of the 
population in the United States28.  Prevalence rates very across the different ADs, with 
the more common ADs being grave’s disease, RA, and hashimoto’s thyroiditis with 
prevalence rates estimated at 500 per 100,000 people28.  Risk factors vary across the 
wide range of ADs, but share some similarities with that of breast cancer, such as race, 
estrogen exposure, and taking certain medications such as hormone replacement 
therapy. 
Among African Americans, the lifetimes risk of developing breast cancer for 
those 80 years of age and younger is 11%, while Caucasians have a 13% risk of 
developing breast cancer.18  However, for those women younger than 45 years, African 
American women tend to have higher rates of breast cancer compared to Caucasian 
women, while the reverse association is true for those over the age of 6018.  Within the 
United States, African Americans have a higher risk for developing SLE and scleroderma 
compared to Caucasians28.  In addition, African Americans also tend to be diagnosed on 
average 7 years younger for both previously mentioned diseases compared to 
Caucasians.  In contrast, the risk for type-I diabetes mellitus and MS is higher among 
Caucasians compared to African Americans, while similar rates are seen for RA28. 
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As mentioned previously those with a Th2 dominant AD were more likely to 
develop breast cancer compared to those with a Th1 dominant AD.  This could be 
because estrogen aids in regulating the Th2 immune response, therefore an increase in 
estrogen results in an increase in the Th2 response11.  Lifetime exposure to estrogen is a 
known risk factor for developing breast cancer.  Women who began their period at age 
12 compared to those at age 14, had a 20% higher risk of developing breast cancer29.  
Lifetime estrogen exposure and breast cancer risk are linearly association, meaning that 
the younger a woman begins her menstrual cycle and the later a woman begins 
menopause the more at risk a woman is to developing breast cancer due to the lifetime 
exposure of estrogen30.       
It has been shown that within the first 2 to 3 years of taking combination 
hormone replacement therapy, breast cancer risk increases by approximately 75% and 
then goes back down 2 years after stopping the medication31.  Hormone replacement 
therapy not only increases the risk of developing breast cancer, but has been shown to 
increase the risk of developing CD as well.  A nested case-control conducted in the 
United Kingdom used frequency-matched controls to determine potential risk factors 
that may be associated with CD or UC.  The results found that the longer-term use of 
hormone replacement therapy significantly increased the risk for developing CD (OR: 
2.60, 95%CI: 1.04 to 6.49)32.  
2.3.4 Breast Cancer Survival Factors and Autoimmune Disease 
While the breast cancer death rate among females has declined by 38% from 
1989 to 2014, breast cancer still remains the second-leading cause of cancer death 
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among women2.  The five-year survival rate for invasive breast carcinoma is 90%, while 
the ten-year survival rate decreases to 83%.  Patient and tumor characteristics have all 
been shown to play a major role in determining survival.   
Patient characteristics that effect breast cancer survival consist of characteristics such as 
age at diagnosis, time after diagnosis, socioeconomic status, and race.  A retrospective 
cohort study conducted on 10,356 women breast cancer patients all under the age of 
50, found that compared to those in the 45 to 49-year age group those who were less 
than 35 years old and those that were between 35 to 39 years of age had a significantly 
higher risk of dying, with an adjusted relative risk of 1.46 (95% CI: 1.27 to 1.70) and 1.26 
(95% CI: 1.12 to 1.42), respectively33.  These results are consistent with other studies, 
and can be attributed to the fact that younger women tend to be at higher risk for 
having a higher histopathologic grade and having tumors that are both larger in size and 
hormone-receptor-negative18,33.  Race also plays a major factor for breast cancer 
survival.  A study found that ten years following treatment 58% of African Americans 
survived compared to the 66% of Caucasian Americans that died, even after adjusting 
for additional prognostic factors there was still a 41% difference between the two racial 
groups18. 
Tumor size has been noted to be one of the strongest indicators of breast cancer 
survival.  The cohort study mentioned previously, found that compared to those with a 
tumor size of 2cm or less, those patients with a tumor size of more than 2cm had a 
significant increase in risk of dying33.  A case-control study assessed the association 
between Hashimoto’s thyroiditis and invasive breast cancer, and found that those with 
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hypothyroidism were significantly more likely to have a smaller tumor size compared to 
those without the AD34.  In addition, Cristofanilli and colleagues found that those with 
hypothyroidism were significantly more likely to be diagnosed with an earlier stage of 
breast cancer than those without the AD34.  Stage, also known as histological grade, has 
been consistently shown to be associated with long-term breast cancer survival among 
those with the lowest score18. 
2.4 Introduction 
Many studies have analyzed the associations between individual autoimmune 
diseases and breast cancer risk.  However, few studies have looked at the association 
between AD and breast cancer survival and even fewer studies have looked at ADs 
collectively.  There are also no known studies that have analyzed the potential 
implications that the Th1 and Th2 dominant ADs have on breast cancer survival.  This 
study will provide an important gap in the literature and will include all ADs that have 
been identified by the American Autoimmune Diseases Association.  In addition, a sub 
analysis will be included to address the potential implications that the Th1 and Th2 





3.1 Purpose and Objectives 
The primary objective of this study was to investigate the association of AD presence 
with breast cancer mortality in a cohort of 3,286 female breast cancer patients.  To 
explore the possible associations between breast cancer survival and AD, the following 
specific aims were proposed: 
1. Assess and compare the baseline patient, tumor, and treatment characteristics 
for those with and without AD among this cohort of female breast cancer 
patients. 
2. Conduct multivariable analyses on the differences in breast cancer specific 
survival among those with and without an AD.  
3. Conduct multivariable analyses on the differences in breast cancer specific 
survival among those that have a T-helper 1 dominant AD, T-helper 2 dominant 
AD, and those without an AD. 
3.2 Hypothesis 
Women with AD will experience an increase in breast cancer survival compared 
to those women without AD.
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3.3 Study Design 
3.3.1 Study Population 
This retrospective cohort study includes 3,286 female breast cancer patients in 
South Carolina that were diagnosed with primary breast cancer between the dates 
January 1, 1996 to December 31, 2010 and are 65 years of age or younger. 
3.3.2 Database 
To create a cohort of diverse women, we linked individual data contained within 
the South Carolina Employee Health Plan, the South Carolina Medicaid Program, South 
Carolina’s National Breast and Cervical Cancer Early Detection Program (Best Chance 
Network), and the South Carolina Central Cancer Registry (SCCR).  This provided us with 
complete data on screening, treatment, mortality, medical procedures, co-morbid 
condition, prescriptions, and corresponding-dates of cancer treatment/services.   
The two administrative claims databases that were used in this study were the 
South Carolina Medicaid Program and the South Carolina Employee State Health Plan.  
Medicaid is considered one of South Carolina’s largest insurance providers and covers 
approximately one-quarter of the state’s population.  The South Carolina Employee 
State Health Plan covers 600 different employer groups in South Carolina, consisting of 
422,000 spouses and dependents, 178,000 active employees, and 63,000 retirees.  The 
Best Chance Network began in 1992, and provides screening services (i.e., 
mammograms, diagnostic procedures, community education, etc.) to underserved 
women that are between the ages of 47 to 64 years.  All women diagnosed in this 
program are subsequently insured through Medicaid for the duration of their breast 
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cancer treatment.  The SCCCR is a population-based data system collecting cancer 
incidence in South Carolina, and has achieved and maintained gold certification 
awarded by the NAACCR since its’ first evaluation in 1997.   
3.3.3 Inclusion and Exclusion Criteria 
To be included in this study, each patient had to be diagnosed with breast cancer 
between the dates January 1, 1996 to December 31, 2010 and have information 
regarding co-morbid conditions and vital status.  This information was provided by the 
SCCCR.  In addition, the patient had to be either African American or European American 
and could have no prior cancer diagnosis to this initial breast cancer diagnosis.  Since 
Medicare was not included in this analysis, all women had to be less than 65 years of 
age.  
3.4 Measurements 
3.4.1 Exposure Variable 
Autoimmune disease was defined by the American Autoimmune Disease 
Association.  This association provided a comprehensive list of ADs that was used to 
identify any patients in the cohort that had an AD.  The International Classification of 
Disease, Ninth Revision (ICD-9), was used to identify the AD.  The ICD-9 codes that were 
used in this study were identified through previous literature and the Find-A-Code 
database, an online database of medical billing codes and information, the codes that 
were used can be seen in table 4.1. 
 In addition, there were two categories of AD, Th1 and Th2 dominant ADs.  These 
were identified through the literature and can be seen in table 2.2 and table 2.3.  The 
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Th1 dominant ADs were defined as patients that had at least one of the following:  
Crohn’s disease, Hashimoto’s thyroiditis/hypothyroidism, Multiple sclerosis, 
Psoriasis/Psoriatic arthritis, Sjögren’s syndrome, Rheumatoid arthritis, Type I diabetes 
mellitus, and Uveitis.  The Th2 dominant ADs were defined as patients that had at least 
one of the following:  Grave’s disease/hypothyroidism, Hemolytic anemia, Immune 
thrombocytopenic purpura, Scleroderma/Systemic Sclerosis, Systemic lupus 
erythematosus, Ulcerative colitis. 
3.4.2 Outcome Variable 
The outcome of interest was breast cancer specific mortality, which was 
ascertained from the SCCCR.  Each year the records in the SCCCR are linked to the 
National Death Index to capture information regarding the date and primary cause of 
death.  The time frame for breast cancer-specific mortality was initiated on the date of 
diagnosis and ended on the date of death.  All non-deceased participants were censored 
December 31, 2013. 
3.4.3 Patient and Clinical Variables 
Variables were collected regarding the patient, tumor, and treatment 
characteristics.  Patient characteristics included age at diagnosis, race, insurance type, 
and year of diagnosis.  Age at diagnosis was analyzed as a continuous variable in this 
study, and race was dichotomized as Caucasian or African American.  Insurance type 
was also dichotomized as type I and type II since due to payor stipulations for data use, 
insurance type was encrypted in our dataset.  Year of diagnosis was grouped into 
categories (2002-2004, 2004-2006, 2008-2010). 
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Tumor characteristics were identified through the SCCCR database and included 
histological grade, estrogen receptor status, progesterone receptor status, hormone 
receptor status, stage, tumor size, and lymph node status.  Both tumor size and lymph 
node status were identified using the TNM classification.  T describes the size of the 
primary tumor, N provides information regarding the extent that the tumor has spread 
to nearby lymph nodes, and M indicates if the cancer has metastasized27.  For tumor 
size, T was used to identify those that were less than or equal to 2cm, those tumors that 
were larger than 2cm but less than 5cm, and those that were over 5cm in diameter.  
Additionally, N captured the number of positive lymph nodes. 
The treatment characteristics of hormone therapy, radiation therapy, and 
chemotherapy were also identified by the SCCCR.  These variables were dichotomized as 
yes/no variables. 
3.5 Statistical Analyses 
Statistical analyses were run using the Statistical Analysis Software (SAS version 
9.2, SAS Institute, Cary, NC).  All statistical tests had an alpha level of 0.05. 
3.5.1 Baseline Data 
Baseline data was stratified by those patients that have at least one AD and 
those that do not have an AD.  Age at diagnosis was treated as a continuous variable 
and analyzed though a t-test, means, standard deviations, and p-values were reported.  
Patient, tumor, and treatment characteristics were categorized, as mentioned in the 
previous section.  Chi-square test were run to determine possible associations between 
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these variables and AD status; corresponding frequencies, row percentages, and p-
values were reported. 
3.5.2 Survival Analysis 
The primary analysis for this study consisted of comparing breast cancer specific 
survival for those with at least one AD and those without an AD, while our secondary 
analysis consisted of comparing those with a Th1 or Th2 dominant AD to those that did 
not have an AD diagnosis.  Survival time was calculated as the date of diagnosis to the 
date of death or date of censoring.  Since breast cancer-specific survival was our primary 
outcome of interest, death due to other causes was censored at the date of death.  
Kaplan Meier, a non-parametric method, along with the Log-rank test was used to 
analyze the difference between the comparison groups for both the primary and 
secondary analysis.  Survival probabilities and corresponding p-values were reported at 
year 3, 5, and 10.   
The Cox proportion hazard regression model was used to estimate the hazard 
ratios (HR) and the corresponding 95% confidence intervals (CI) for breast-cancer 
specific mortality.  Based on previous literature the following variables were considered 
for the final fully-adjusted model: race, insurance type, year of diagnosis, stage, 
radiation therapy, chemotherapy, and hormone therapy.  Hormone receptor status was 
not considered for the model, due to the collinearity that exists between both hormone 
receptor status and hormone therapy.  A collinear pattern also exists for stage, grade, 
and lymph node status; since there were more participants with information regarding 
stage compared to the other two variables, stage was considered for the model.  The 
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proportional hazard assumption for the covariates was assessed using Schoenfeld 
residuals.  Covariates were stratified in the models if they failed to meet the 
proportionality assumption.  Unadjusted models were analyzed along with models that 





Among the 3,286 women diagnosed with breast cancer between 1996 to 2010, 
there were 513 breast cancer-specific deaths and 639 total deaths were reported.  
19.14% of participants had at least one AD prior to the initial breast cancer diagnosis.  
The most common ADs within this study were rheumatoid arthritis, type I diabetes 
mellitus, and antiphospholipid syndrome (Table 4.1). 
The average age of breast cancer diagnosis for a participant with an AD was 
significantly different from that of a participant without an AD, at 52 years versus 50 
years, respectively.  Those with an AD were more likely to have Type I insurance 
compared to those participants without an AD.  However, no additional differences 
were observed between the two groups (Table 4.2). 
4.1 Primary Outcome 
No associations were observed between those with an AD and those without an 
AD for both breast cancer-specific survival or all-cause survival (Figure 4.1 and 4.2).  For 
breast cancer-specific survival, the probability of survival was slightly lower for those 
with an AD at 3, 5, and 10 years post-diagnosis (Table 4.4).  For all-cause survival, those 
with an AD had a slightly higher probability of survival (0.89) compared to those without 
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an AD (0.87) 3 years post-diagnosis.   
 Cox models were initially run with the following covariates:  race, insurance type, 
stage, hormone medication, chemotherapy, and radiation.  When the proportional 
hazard assumption was tested with the variables mentioned previously, race, insurance 
type, stage, hormone medication, and radiation therapy violated the assumption.  Both 
adjusted and unadjusted models were run and stratified by the variables that failed to 
meet the proportional hazard assumption (Table 4.6).  Models were adjusted for by 
chemotherapy.  Among African Americans, those with an AD had a 5% reduction in 
breast cancer mortality compared to those without an AD, while the inverse occurred 
for European Americans with a 11% increase in breast cancer mortality among those 
with an AD.  This inverse association remained when controlling for chemotherapy.  An 
inverse relationship occurred for stage as well.  Compared to those without an AD, 
those with an AD had a reduction in breast cancer mortality when they had a carcinoma 
that was in-situ or local (HR: 0.89, 95% CI: 0.55, 1.44) and an increase in mortality for 
those with a carcinoma that was regional or distant (HR: 1.16, 95% CI: 0.91, 1.49).  There 
was a 51% increase in breast cancer mortality among patients that did not receive 
radiation therapy and had an AD compared to those that did not have an AD.  However, 
when controlling for chemotherapy there was a 17% increase in breast cancer mortality 
among AD patients compared to non-AD patients.  There was a 9% reduction in breast 
cancer mortality among the AD patients that received radiation therapy compared to 
those non-AD patients.  The bivariate adjusted and unadjusted Cox models for both 
insurance type and hormone medication showed an overall increase in breast cancer 
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mortality among patients with an AD.  There was a 6% increase in breast cancer 
mortality among patients with an AD compared to those without an AD, and a 9% 
increase when controlling for chemotherapy. 
Table 4.1:  Autoimmune disease frequencies and ICD-9 codes. 









279.00, 279.06 3 (0.38) 
36,37 
Alopecia areata 704.01 12 (1.51) 
38 




Autoimmune hepatitis 571.42, 571.49 10 (1.26) 
35 
Behcet’s disease 136.1 1 (0.13) 
41 
Bullous pemphigoid 694.5 1 (0.13) 
36 
Celiac disease 579.0 2 (0.25) 
42,43 





357.81 1 (0.13) 
36 




710.3 1 (0.13) 
41,46 
Discoid lupus 695.4 10 (1.26) 
43,47 
Erythema nodosum 695.2 2 (0.25) 
48 
Evan’s syndrome 287.32 1 (0.13) 
36 
Fibrosing alveolitis 516.3 5 (0.63) 
49 
Giant cell arteritis 446.5 8 (1.01) 
45 






242.00, 242.01 24 (3.03) 
35,41,43 




245.2 21 (2.65) 
35,41,51,43 
Hemolytic anemia 283.0  
35,36 




287.31, 287.3, 287.30, 





Interstitial cystitis 595.1 20 (2.52) 
36 
Lichens planus 697.0 10 (1.26) 
52 
Lichen sclerosus 701.0 16 (2.02) 
36 
Meniere’s disease 386.0, 386.00, 386.01 9 (1.14) 
36 
Mucha-Habermann disease 696.2 1 (0.13) 
36 
Multiple sclerosis 340 13 (1.64) 
35,43–45 
Myasthenia gravis 358.00 1 (0.13) 
35,41,44 
Neutropenia 288.09 9 (1.14) 
36 
Optic neuritis 377.30 5 (0.63) 
36 




Pernicious anemia 281.0 36 (4.55) 
35,43,47 
Polyarteritis nodosa 446.0 2 (0.25) 
43,47 
Polymyaglia rheumatica 725 11 (1.39) 
43,46,47 
Primary biliary cirrhosis  571.6 1 (0.13) 
35,43,47 
Primary sclerosing cholangitis 576.1 1 (0.13) 
36 
Psoriasis/Psoriatic arthritis2 696.0, 696.1, 696.8 46 (5.82) 
37,45,53 
Raynaud’s phenomenon 443.0 9 (1.14) 
48 
Retroperitoneal fibrosis 593.4 4 (0.51) 
36 
Rheumatoid arthritis 714.0, 714.1, 714.2, 714.30 82 (10.37) 
35,41,43,44,53,54 
Rheumatic fever 390, 391.0 3 (0.38) 
35,43,47 
Sarcoidosis 135 24 (3.03) 
43,47 
Scleroderma3 710.1, 701.0 4 (0.51 
35,41,46,43 




421.0 1 (0.13) 
36 
Systemic lupus erythematosus 710.0 22 (2.78) 
35,41,43,46 
Type I diabetes mellitus  250.01, 250.03 126 (15.93) 
35,45 








Vitiligo 709.01 4 (0.51) 
35 
Wegner’s granulomatosis 446.4 1 (0.13) 
50,47 
1Agammaglobulinemia and hypogammaglobulinemia were placed in the same category 
since the    same ICD-9 code is used for both diseases 
2Psoriasis and Psoriatic arthritis were placed in the same category since the same ICD-9 
code is used for both diseases 
3This includes both systemic sclerosis and localized scleroderma 
4All ICD-9 codes that were included in this table were only the codes that were present 
in this study, the other codes not included in this table that were present in the study 




Table 4.2:  Baseline patient, tumor, and treatment characteristics of breast cancer 
patients with and without an AD. 
 Patients with AD 
(n=629) 
Patients without AD 
(n=2657) 
p-value1 
Patient Characteristics    
Age at diagnosis 52.05 ± 6.55 50.14 ± 7.83 <.0001 
Race    
African American 228 (20.73) 872 (79.27) 0.1013 
Caucasian 401 (18.34) 1785 (81.66)  
Geographic location    
Urban 479 (19.38) 1992 (80.62) 0.5375 
Rural 150 (18.40) 665 (81.60)  
Insurance    
Type I 417 (20.41) 1626 (79.59) 0.0177 
Type II 212 (17.06) 1031 (82.94)  
Year of Diagnosis    
2002-2004 175 (17.61) 819 (82.39) 0.3357 
2005-2007 203 (19.90) 817 (80.10)  
2008-2010 251 (19.73) 1021 (80.27)  
Tumor Characteristics    
Histological Grade    
I 93 (19.02) 396 (80.98) 0.3975 
II and III 471 (19.42) 1954 (80.58)  
IV 7 (12.28) 50 (87.72)  
Missing 58 257  
Estrogen Receptor Status    
ER+ 236 (18.88) 1014 (81.12) 0.2265 
ER- 119 (21.33) 439 (78.67)  
Missing 274 1204  
Progesterone Receptor 
Status 
   
PR+ 196 (18.33) 873 (81.67) 0.1111 
PR- 156 (21.37) 574 (78.63)  
Missing 277 1210  
Hormone Receptor Status    
ER+/PR+ 183 (17.91) 839 (82.09) 0.1022 
ER+/PR- 49 (22.90) 165 (77.10)  
ER-/PR+ 13 (28.89) 32 (71.11)  
ER-/PR- 106 (20.70) 406 (79.30)  
Missing 278 1215  
Stage    
In-situ 101 (18.20) 454 (81.80) 0.4744 
Local 275 (19.70) 1121 (80.30)  
Regional 220 (19.75) 894 (80.25)  
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Distant 28 (15.38) 154 (84.62)  
Missing 5 34  
Tumor Size    
≤2cm 212 (19.78) 860 (80.22) 0.8498 
>2cm-5cm 143 (20.40) 558 (79.60)  
>5cm 36 (21.56) 131 (78.44)  
Missing 238 1108  
Lymph Node Status    
Positive 316 (19.73) 1286 (80.27) 0.8364 
Negative 188 (20.06) 749 (79.94)  
Missing 125 662  
Treatment 
Characteristics 
   
Hormone Therapy    
Yes 386 (19.36) 1608 (80.64) 0.6955 
No 243 (18.81) 1049 (81.19)  
Chemotherapy    
Yes 301 (19.16) 1270 (80.84) 0.9759 
No 308 (19.20) 1296 (80.80)  
Missing 20 91  
Radiation Therapy    
Yes 268 (18.95) 1146 (81.05) 0.7698 
No 352 (19.36) 1466 (80.64)  
Missing 9 45  
1P-values were calculated using a t-test for continuous variables (the corresponding 
mean and standard errors were reported), and a chi-square test for categorical variables 
(the corresponding frequencies and row percentages were reported) 
Abbreviations used:  ER (estrogen), PR (progesterone), AD (autoimmune disease) 
 
Table 4.3:  Cause of death among those with and without an AD. 
Cause of death Patients with AD (n=629) Patients without AD 
(n=2657) 
p-value1 
Alive 493 (18.62) 2154 (81.38) 0.0209 
Breast 100 (19.49) 413 (80.51)  
Other 36 (28.57) 90 (71.43)  
1P-values were calculated using chi-square test (the corresponding frequencies and row 
percentages were reported) 
















Figure 4.1:  Breast cancer specific survival for those diagnosed with at least one AD 









Figure 4.2:  All cause survival for those with at least one AD (indicated by the red line) 
and those without an AD (indicated by the blue line). 
 
Table 4.4:  Three, five, and ten-year survival comparison among those with and 
without an AD. 






p-value1 Probability of 
Survival 
p-value1 
Year 3     
AD  0.8855 0.2811 0.9011 0.8763 
No AD 0.8712  0.9009  
Year 5     
AD  0.7998 0.0391 0.8449 0.4728 
No AD 0.8371  0.8594  
Year 10     
AD  0.7442 0.0825 0.8108 0.5677 
No AD 0.7742  0.8190  
1 P-values were calculated using the log rank test 




Table 4.5:  Cox model for breast cancer specific mortality among those with and 





Unadjusted analysis Multivariable analysis1 
HR 95% CI HR 95% CI 





AD (629) 136 1.06 0.85, 1.32 1.09 0.88, 1.36 
1Adjusted for chemotherapy 
Abbreviations used: AD (autoimmune disease), HR (hazard ratio), CI (confidence 
interval) 
 
Table 4.6:  Bivariate Cox model for breast cancer specific mortality among those with 
and without an AD. 
Stratum variables 




Unadjusted analysis Multivariable analysis1 
HR 95% CI HR 95% CI 
Race      
African American      





AD (228) 63 0.949 0.69, 1.30 0.99 0.72, 1.35 








AD (401) 73 1.11 0.82, 1.50 1.14 0.83, 1.55 
Insurance      








AD (417) 50 1.22 0.85, 1.74 1.27 0.89, 1.82 








AD (212) 86 1.12 0.85, 1.47 1.14 0.86, 1.51 
Stage      








AD (389) 42 0.89 0.55, 1.44 0.90 0.55, 1.47 
Regional and distant      










     








AD (386) 63 1.11 0.80, 1.54 1.14 0.82, 1.59 








AD (243) 73 1.03 0.77, 1.39 1.09 0.81, 1.48 
Radiation therapy      








AD (268) 43 0.91 0.62, 1.33 0.97 0.67, 1.42 








AD (352) 91 1.51 0.88, 1.51 1.17 0.89, 1.54 
1Adjusted for chemotherapy 
Abbreviations used: AD (autoimmune disease), HR (hazard ratio), CI (confidence 
interval) 
 
4.2 Secondary outcome 
Among the Th1, Th2 dominant AD, and no AD cohorts breast cancer-specific 
survival was statistically significant (Figure 4.7).  The probability of survival was greater 
among the Th1 group compared to the other two groups at all three-time points (Table 
4.8).  Compared to those without an AD those with a Th2 dominant AD also had a higher 
probability of breast cancer-specific survival.  All-cause survival was not statistically 
significant (Figure 4.3), but at 3-years post-diagnosis that was a significant difference 
between the cohorts, with the same pattern that was seen for breast cancer-specific 
survival.  However, at year 10 those that were in the Th2 cohort had a lower probability 
survival than those that did not have an AD. 
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Cox models were used to determine the risk of breast cancer mortality among 
the three groups.  Models were stratified by race, insurance, stage, and hormone 
medication due to the time dependence that is associated with these variables.  
Adjusted models controlled for both chemotherapy and radiation therapy.  There was a 
significant reduction in breast cancer mortality for both for those with a Th1 AD 
compared to those without an AD (HR: 0.46, 95% CI: 0.25, 0.87).  This relationship 
remained significant when controlling for both chemotherapy and radiation therapy 
with a 55% reduction in breast cancer mortality.  A reduction in breast cancer mortality 
was also seen for both the adjusted and unadjusted Cox models for those patients with 
a Th2 dominant AD, however results were not significant.  Among those with breast 
carcinoma that was either regional or distant, there was a significant reduction in breast 
cancer mortality in both the unadjusted and adjusted Cox models when comparing 
those patients with a Th1 AD to those without an AD with a HR of 0.46 (95% CI: 0.23, 
0.92) and 0.44 (95% CI: 0.21, 0.93), respectively.  However, those with a Th2 AD had an 
increase in breast cancer mortality for both the unadjusted and adjusted Cox models 





Table 4.7:  Cause of death among those with a Th1 dominant and Th2 dominant AD 
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and those without an AD. 
Cause of 
death 
Patients with a 
Th1 AD (n = 
136) 
Patients with a 
Th2 AD (n = 53) 
Patients 
without an AD 
(n = 2657) 
 p-value1 
Alive 121 (5.22) 42 (1.81) 2154 (92.97)  0.0128 
Breast 10 (2.33) 6 (1.40) 413 (96.27)   
Other 5 (5.00) 5 (5.00) 90 (90.00)   
1P-values were calculated using chi-square test (the corresponding frequencies and row 
percentages were reported) 















Figure 4.3:  Breast cancer specific survival for those diagnosed with Th1 dominant AD 
(indicated by the red line), Th2 dominant AD (indicated by the green line), and no AD 

















Figure 4.4:  All cause survival for those diagnosed with Th1 dominant AD (indicated by 
the red line), Th2 dominant AD (indicated by the green line), and no AD (indicated by 
the blue line). 
 
Table 4.8:  Three, five, and ten-year survival comparison among those with a Th1 
dominant and Th2 dominant AD and those without an AD. 
 All Cause Survival Breast Cancer Specific 
Survival 




p-value1 Probability of 
Survival 
p-value1 
Year 3     
Th1 AD 0.9559 0.0344 0.9630 0.0197 
Th2 AD 0.9245  0.9612  
No AD 0.8855  0.9009  
Year 5     
Th1 AD 0.8946 0.1466 0.9260 0.0358 
Th2 AD 0.8417  0.9170  
No AD 0.8371  0.8594  
Year 10     
Th1 AD 0.8593 0.0999 0.9142 0.0378 
Th2 AD 0.7156  0.8420  
No AD 0.7742  0.8190  
1 All p-values were determined by the log rank test 
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Abbreviations used:  AD (autoimmune disease), Th1 (T-helper 1), Th2 (T-helper 2) 
 
Table 4.9:  Cox model breast cancer specific mortality among those with a Th1 
dominant and Th2 dominant AD and those without an AD. 




Unadjusted analysis Multivariable analysis1 
HR 95% CI HR 95% CI 





Th1 AD (136) 15 0.46 0.25, 0.87 0.45 0.23, 0.87 
Th2 AD (53) 11 0.70 0.31, 1.58 0.71 0.32, 1.60 
1Adjusted for chemotherapy and radiation therapy 
Abbreviations used: AD (autoimmune disease), Th1 (T-helper 1), Th2 (T-helper 2), HR 
(hazard ratio), CI (confidence interval) 
 
Table 4.10:  Bivariate Cox model for breast cancer specific mortality among those with 
a Th1 dominant and Th2 dominant AD and those without an AD. 
Stratum variables 




Unadjusted analysis Multivariable analysis1 
HR 95% CI HR 95% CI 
Race      
African American      





Th1 AD (47) 6 0.45 0.19, 1.09 0.48 0.20, 1.17 
Th2 AD (20) 4 0.39 0.10, 1.58 0.34 0.08, 1.37 








AD (89) 9 0.46 0.19, 1.12 0.40 0.15, 1.08 
Th2 AD (33) 7 1.02 0.38, 2.75 1.18 0.44, 3.18 
Insurance      








Th1 AD (97) 7 0.66 0.27, 1.61 0.70 0.29, 1.71 
Th2 AD (34) 3 0.70 0.17, 2.83 0.70 0.17, 2.83 








Th1 AD (39) 8 0.45 0.19, 1.09 0.40 0.15, 1.08 
Th2 AD (19) 8 0.75 0.28, 2.02 0.76 0.28, 2.04 
Stage      
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Th1 AD (82) 5 0.49 0.12, 2.00 0.50 0.12, 2.04 
Th2 AD (39) 5 0.51 0.07, 3.69 0.48 0.07, 3.46 








Th1 AD (53) 10 0.46 0.23, 0.92 0.44 0.21, 0.93 
Th2 AD (14) 6 1.09 0.45, 2.63 1.07 0.44, 2.60 
Hormone 
medication 
     








Th1 AD (84) 6 0.33 0.11, 1.03 0.33 0.11, 1.03 
Th2 AD (29) 4 0.61 0.15, 2.46 0.55 0.14, 2.21 








Th1 AD (52) 9 0.57 0.27, 1.20 0.61 0.27, 1.38 
Th2 AD (24) 7 0.69 0.26, 1.84 0.90 0.34, 2.43 
1Adjusted for chemotherapy and radiation therapy 
Abbreviations used: AD (autoimmune disease), Th1 (T-helper 1), Th2 (T-helper 2), HR 






Our study found that there was a significant difference in breast cancer-specific 
survival among those with a Th1 dominant AD versus those without an AD diagnosis.  
This research suggests that the Th1 immune response that is associated with the Th1 
dominant ADs may play a protective role for breast cancer mortality.  This study was the 
first of its kind to analyze the association between breast cancer survival and the 
hypothesized Th1 and Th2 dominant ADs.   
An autoimmune disease occurs when B cells develop antibodies to the body’s 
organs and/or tissues, resulting in an attack on the body’s otherwise healthy organs and 
tissues10.  The T helper cells, Th1 and Th2, coordinate and direct the B cells.  The Th1 
cytokines enhance the antitumor immune response through the secretion of IFN-ƴ, 
causing the anti-tumor directed B cell factors and the CD8+ T cells to all work together 
to “favor tumor rejection”4.  In contrast, the Th2 cytokines secrete pro-growth factors 
which ultimately decrease the CD8+ T lymphocytes, resulting in tumor promotion4.  This 
biological plausibility aligns with the results of this study, showing that the Th1 
dominant ADs, Crohn’s disease, Hashimoto’s thyroiditis, Multiple Sclerosis, Psoriasis, 
Sjögren’s syndrome, Rheumatoid arthritis, Type I diabetes mellitus, and Uveitis, 
collectively play a protective role in reducing breast cancer mortality.  The conclusions
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of this study are consistent with that of other studies.  A study conducted by Campbell 
and colleagues analyzed the peripheral blood lymphocytes of 84 breast cancer patients 
and 26 healthy controls, and found that Th1 cytokines were significantly lower in breast 
cancer patients prior to treatment compared to the healthy controls21.  An additional 
study conducted on over 12,000 breast cancer patients in the United Kingdom and 
Canada found that among the women with estrogen receptor negative tumors, the 
presence of CD8+ T cells within the tumor, a response that is linked with an increase in 
Th1 cytokines, was significantly associated with a 28% reduction in breast cancer 
mortality20.   
While there have been no studies to date looking at the association between the 
Th1 dominant ADs and cancer mortality, there have been a few studies that have 
analyzed the association that exists individually for the Th1 ADs that have been 
identified in this study.  A cohort study conducted in Ontario, Canada identified 178,186 
women with breast cancer and found that those with Hashimoto’s thyroiditis had a 
significantly lower risk of dying compared to those that did not have an AD (HR: 0.87, 
95% CI: 0.77 to 0.98)1.  Hemminki and colleagues conducted a study in Sweden, 
analyzing the risk and survival of female cancers for individuals ADs, finding a significant 
reduction in breast cancer mortality among psoriasis patients (HR: 0.68, 95% CI: 0.50 to 
0.94)25.   
Strengths of this study include the comprehensive records of each patient that 
encompassed the medical claims information from the Best Chance Network and the 
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vital status information of each individual from the SCCCR, which updates its’ database 
using the National Death Index and the South Carolina Vital Registry.  In addition, the 
use of both the South Carolina Employee State Health Plan and the South Carolina 
Medicaid Program provided a cohort of women that are racially, geographically, and 
socioeconomically diverse, providing strong external validity for this study.  A weakness 
of this present study was the unavailability of data for age at menarche and menopause, 
oral contraception, and hormone replacement therapy, all factors that have been 
associated with both breast cancer and AD.  Many studies have attributed a reduced risk 
of cancer seen among individual ADs to immunosuppressive therapy and anti-
inflammatory drug therapies that are often used among AD patients25.  Studies have 
suggested a link between these therapies and an earlier age at menopause, thus 
reducing the risk of developing breast cancer25.  Future studies are needed to look at the 
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